There are situations where the normal architecture and biomechanics of the foot (specifically the medial column) becomes significantly altered. Gait disturbances, skin abnormalities, and ulcerations can develop leading to infections and even possible amputation. This may be painful if sensation is intact. Often, however, decreased sensation is part of the cause.

The causes include posttraumatic cases, inflammatory diseases such as rheumatoid arthritis, and rare problems such as Marfans disease or neuromuscular tertiary syphilis and paralytic diseases. A common reason today is the increasing population of patients with diabetic neuropathy sometimes causing neuroarthropathy.

These patients may be treated nonoperatively in an orthosis or total contact cast in an attempt to consolidate the unstable foot. However, this is a labor intensive and potentially costly process. The outcome is not always satisfactory.

If the initial treatment has been nonoperative, the further treatment often remains nonoperative. Some are ambulating in calipers and orthoses to relieve pressure from threatening ulcers, others in expensive customized shoes that they object to for cosmetic reasons. The quality of life is diminished immensely for someone with a Charcot foot, and also puts a high cost on health care systems.

A possible solution for pressure points is the bumpectomy (local resection of protruding bone with no stabilization). If the joint segments are still unstable (the more common situation) the deformity will however progress.

This is why a reconstructive realignment usually is necessary to achieve a more normal weight bearing and alignment of the foot.

The first recognized success of such treatment was in the early 1990s in Seattle by Sigvard T Hansen, Jr. In many cases, the patient had a longstanding pressure wound on the plantar surface of the foot. Reconstruction was carried out in the presence of an open ulcer, which was covered by a biodressing during the procedure on the rest of the foot. After surgical reconstruction removed the unnatural pressure on the soft tissues, the ulcer disappeared within a few weeks.

Even very heavy/thick screws fail in these patients (especially as the patients are getting heavier with time). The 6.5mm Midfoot Fudion Bolt has been developed specifically to treat the forces and demands in the midfoot area.

The MFB is available in lengths of 50160 mm in titanium and stainless steel.

The Foot and Ankle Expert Group wanted the MFB to be a simple, strong, easy-to-use implant because Charcot foot collpase will be more prevalent over the coming years. First, it needs to be said that it is not meant as a compressive screw. The compression should be achieved by other implantsscrews or plates that are added. The threads on the MFB are intended to keep the bolt where it is positioned.

The standard approach to release the midfoot and to produce the necessary corrections is the medial utility incision. It can be extended all along the medial foot from medial malleolus region to the medial hallux. There are several options for the introduction of the implant along the medial column:

1. The main track is through the MTP1 transarticularly. With minimal dissection the cannulated drilling and MFB insertion is done with the great toe flexed downwards.
2. A variant is to perform a distal osteotomy shift the head of MT1 laterally (chevron-type) and perform the implantation (adapted in a patient with sensation).
3. A third variant is the retroantegrade techniquedrilling over the wire in an antegrade fashionintroducing the screw the same way. This lessens the damage in MTP 1 but harms the ankle instead.

On the lateral side of the foot the drill wire is passed through MT 4 cuboid and out through calcaneus while the foot is maintained in the desired alignment. The wire is then overdrilled antegrade from back to front and the bolt is inserted.

The entry point in MT 4 is 22,5 cm from the TMT joint to achieve some grip with the bolt.

The postoperative treatment is immobilization in a splint for 2 weeks to reduce swelling. At 2 weeks, the wound is evaluated and gentle range of motion training of joints is initiated. Full weight bearing is anticipated between 1012 weeks postop based on radiographical evidence of healing.

Producing a stable construct before the foot has progressed to an advanced deformity, when the start of the breakdown is detected, may lead to a better, more reliable result with a better quality of life for these patients. It is also anticipated to lower the high costs of healthcare in diabetic foot clinics and for amputations and prostheses.

There is data in literature in this direction and therefore a randomizedcontrolled multicenter study run by AO Clinical Investigation and Documentation (CID) is being initiated to compare the effectiveness of surgical arthrodesis with MFB in the early stage of diabetic-neuropathic Charcot feet. This will be compared to nonoperative treatment in terms of maintenance of the correction of the deformity and avoidance of permanent nonreducible foot deformity.